南昌精神病医院在那治疗双相情感障碍南昌那家医院收费少,南昌市第十二医院治精神科口碑好么正规么,南昌专治精神病医院哪家最好,南昌医院酒瘾哪家好,南昌那家医院治躁狂比较好一点,南昌治躁狂症那个医院,南昌治强迫症的中医

WASHINGTON, Jan. 19 (Xinhua) -- New research published this week in Nature Medicine indicates that targeted drugs such as gefitinib might more effectively treat non-small cell lung cancer if they could be combined with agents that block certain microRNAs.The study, led by investigators with the Ohio State University Comprehensive Cancer Center, shows that overexpression of two genes called MET and EGFR causes the deregulation of six microRNAs, and that this deregulation leads to gefitinib resistance.The findings support the development of agents that restore the levels of these microRNAs. It offers a new strategy for treating non-small cell lung cancer, which is responsible for about 85 percent of the 221,000 lung-cancer cases and 157,000 deaths that occur annually in the United States. It also suggests that measuring the expression levels of certain microRNAs -- those controlled by the MET gene -- might predict which lung-cancer cases are likely to be resistant to gefitinib.Epidermal growth factor receptor (EGFR) is frequently overexpressed in non-small cell lung cancer, and this leads to uncontrolled cell proliferation. Gefitinib selectively inhibits EGFR activation and triggers cancer cells to self-destruct by apoptosis. However, non-small cell lung cancer cells inevitably develop resistance to the drug. The study reveals how this resistance occurs."Our findings suggest that gefitinib resistance that is caused by MET overexpression is at least partly due to miRNA deregulation, " says principal investigator Carlo Croce.

UNITED NATIONS, Jan. 24 (Xinhua) -- China welcomes and supports all efforts and measures that would break the current deadlock of the Palestinian-Israeli negotiation and relaunch their dialogues, Chinese UN ambassador Li Baodong said here Tuesday.Li made the remarks when addressing a Security Council monthly open debate on Middle East."The Middle East peace process is currently in a stalemate. China is deeply concerned over the development," Li said."We always maintain that the parties concerned should resolve their disputes through political negotiations under the relevant UN resolutions, the principle of 'land for peace,' the Arab Peace Initiative and the Middle East Roadmap for Peace with the goal of ultimately establishing an independent Palestinian state and two states,Palestine and Israel, living side by side in peace," he said. China appreciates the efforts made recently by Jordan and Quartet of Middle East to facilitate the two parties to have direct contact, said Li, adding "We hope the relevant peace promotion efforts will help resume the Palestinian-Israeli peace negotiation sooner and achieve substantive result. China supports a greater role of the UN in resolving the Middle East issue."Calling the Israeli settlement "a major obstacle" for the resumption of Palestinian-Israel peace negotiation, Li said China is seriously concerned about the recent approval by the Israeli government of plans for expansion of new settlements."China is always against Israeli establishment of Jewish settlements in the occupied Palestinian territory including East Jerusalem. We urge Israel to cease the settlement construction immediately, be prudent in action and work actively in collaboration with the efforts of the international community to promote peace, and create conditions for the resumption Palestinian-Israeli peace negotiation," the ambassador said.China has always supported the Palestinian people in their just cause to restore the lawful rights of the nation, and maintained that establishment of an independent state is the lawful right of the Palestinian people as the basis for the implementation of the "two-state solution""China supports the establishment of an independent Palestinian state that enjoys full sovereignty, with East Jerusalem as its capital and based on the 1967 border. China supports Palestine's membership in the United Nation," Li said.The Syria-Israel track and the Lebanon-Israel track are important component of the Middle East peace process, and play an indispensable role in the overall settlement of the Middle East issue, Li said.China firmly supports the just cause of Syria and Lebanon to maintain sovereignty and territorial integrity, and recover their occupied territoriesChina supports the strategic choice made by Arab states in their pursuit of a comprehensive and lasting peace in the region, Li added.He also called on relevant parties to keep constrained, avoid the escalation of tension in Gaza, effectively implement relevant UN resolutions and fully lift the Gaza blockade.

WASHINGTON, Dec. 21 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Wednesday approved Isentress for the treatment of HIV-1 infection for children and adolescents.The drug is part of a class of medications called HIV integrase strand transfer inhibitors that works by slowing the spread of HIV in the body. It was first approved for use in adult patients in October 2007, under FDA's accelerated approval program."Many young children and adolescents are living with HIV and this approval provides an important additional option for their treatment," said Edward Cox, director of the Office of Antimicrobial Products in the FDA's Center for Drug Evaluation and Research.Isentress is a pill that can be taken twice daily, with or without food. The pill is also available in a chewable form. As the two tablet formulations are not interchangeable, the chewable form is only approved for use in children ages 2 to 11.A single, multi-center clinical trial of 96 children and adolescents aged 2-18 years with HIV-1 infection evaluated the safety and effectiveness of Isentress. These patients previously received treatment for HIV-1 infection. After 24 weeks of treatment with Isentress, 53 percent of these patients had an undetectable amount of HIV in their blood.According to the FDA, the most commonly reported severe, treatment-related side effects in patients taking Isentress include trouble sleeping and headache. The frequency of these side effects is similar for children and adults. One pediatric patient reported severe treatment-related insomnia, while another pediatric patient experienced a drug-related skin rash.

WASHINGTON, Oct. 13 (Xinhua) -- In a trial that included about 35,000 men, those who were randomized to receive daily supplementation with vitamin E had a significantly increased risk of prostate cancer, according to a study published this week in the Journal of the American Medical Association.The study followed more than 35,533 men 50 or older at 427 sites in the United States, Canada and Puerto Rico. The men were divided into four groups who took daily doses of 400 international units of Vitamin E and 200 micrograms of selenium; Vitamin E and a placebo that looked like selenium; selenium and a placebo that looked like Vitamin E; or two placebos. The recommended daily intake of Vitamin E is about 22.4 international units.The researchers from the Cleveland Clinic found that the rate of prostate cancer detection was greater in all treatment groups when compared with placebo but was statistically significant only in the vitamin E alone group -- a 17 percent increased rate of prostate cancer detection. The difference in rates of prostate cancer between vitamin E and placebo became apparent during the participants' third year in the trial. The elevated risk estimate for vitamin E was consistent across both low- and high-grade disease."The observed 17 percent increase in prostate cancer incidence demonstrates the potential for seemingly innocuous yet biologically active substances such as vitamins to cause harm. The lack of benefit from dietary supplementation with vitamin E or other agents with respect to preventing common health conditions and cancers or improving overall survival, and their potential harm, underscore the need for consumers to be skeptical of health claims for unregulated over-the-counter products in the absence of strong evidence of benefit demonstrated in clinical trials," the researchers said.

SHENYANG, Nov. 17 (Xinhua) -- A MD-90 aircraft left the northeastern city of Shenyang for its American home on Thursday, ending the service of the last McDonnell-Douglas jet for Chinese airlines.Chinese carriers will no longer operate MD-made jets due to growing market demands, said Lu Changchun, deputy general manager with the north China branch of China Southern Airlines, which has operated the MD-90 jet for over a decade.MD-90 jets were involved in no accidents during the decade-long-service in China, so safety concerns did not lead to their retirement, Lu said, adding about 1,000 MD-90 jets are still flying around the world.Lu, however, admitted that supply of aircraft materials was affected as the production line of MD jets shrank, after McDonnell-Douglas Cooperation was merged into Boeing in 1997.MD jets were replaced mainly because Chinese airlines need new models to accommodate air travel demands fueled by the economic boom, Lu said.The north China branch of China Southern Airlines also announced Thursday the retirement of five A300-600R planes, which are replaced by A320 family jets. China Southern Airlines began flying an Airbus A380 superjumbo in China in October.China's domestic air travel market is predicted to grow 13.9 percent annually by 2014 and transport 379 million domestic air passengers, which will make the country the world's second-largest air travel market after the United States, according to a report released by the International Air Transport Association.Back in the 1990s, a Shanghai-based aircraft maker assembled two MD-90 jets in China, Lu said, adding the two jets retired this year.Change of jets model serves the strategic transformation of China Southern Airlines and meets the market demands, Lu said.Li Jiaxiang, chief of China's civil aviation administration, estimated that over 1.5 trillion yuan (235 billion U.S. dollars) will be invested in the civil aviation industry by 2015, adding about 2,000 aircraft to the country's fleet.Commercial Aircraft Corporation of China, producer of China's first self-developed jumbo jet, the C919, has announced that it will complete the design for the passenger plane in 2012. The jet is expected to take off in 2014 and put into service in 2016.